Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report issued Tuesday, Credit Suisse’s European Pharma Team revisited its model for ocrelizumab. Following the release of data that suggested the drug is a best-in-class in relapsing-remitting multiple sclerosis (and that shows its tolerability profile is “impressive”), the firm assigned a 90 percent probability of $5.5 billion across MS indications.
Given the high unmet need in PPMS, the experts see “early launch potential and believe that accelerated review is a significant possibility.” Their model assumes roughly $1 billion in sales in 2017.
On the other hand, the analysts expect some of the revenue benefit to be offset by the significant investment needed to launch ocrelizumab – especially within the MS infrastructure. Moreover, they noted, “This will coincide with a substantial investment in I-O phase 3.”
Investment Case And Catalysts
Credit Suisse analysts still think Roche has “significant underappreciated late-stage pipeline/launch potential with Esbriet, PD-L1, ocrelizumab, venetoclax, ACE910, lebrikizumab and potentially Perjeta in adjuvant HER2+ breast.” Thus, they envision material upside to mid-term consensus estimates on a positive launch of ocrelizumab and other clinical outcomes.
Among the upcoming catalysts, the experts highlighted:
- Third-quarter results, scheduled for October 22.
- ASH in early December: Venetoclax pivotal P2.
- SABC around mid-December: Atezo breast POC.
- For the first half of 2016: Perjeta P3 APHINITY adjuvant breast.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
Image Credit: Public DomainCrypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!